Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.
You may also be interested in...
QT prolongation appears to have been one of the primary safety considerations during FDA’s review of Bristol-Myers Squibb’s leukemia treatment Sprycel (dasatinib), review documents suggest.
Review documents for Pfizer's Sutent show early, pre-NDA concern within FDA's oncology division relating to the multi-targeted tyrosine kinase inhibitor's potential to cause adrenal toxicity
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.